SAM CHUN DANG PHARM CO. LTD
000250 | KO
Overview
Corporate Details
- ISIN(s):
- KR7000250001
- LEI:
- Country:
- South Korea
- Address:
- 경기도 화성시 향남읍 제약공단2길 71, 화성시
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-19 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(교환사채권발행결정)
|
Korean | 30.5 KB | ||
| 2025-09-19 00:00 |
Transaction in Own Shares
[기재정정]주요사항보고서(자기주식처분결정)
|
Korean | 40.4 KB | ||
| 2025-09-19 00:00 |
Transaction in Own Shares
자기주식처분결과보고서
|
Korean | 22.0 KB | ||
| 2025-09-19 00:00 |
Share Issue/Capital Change
증권발행결과(자율공시)
|
Korean | 7.4 KB | ||
| 2025-08-27 00:00 |
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
|
Korean | 25.0 KB | ||
| 2025-08-27 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
|
Korean | 32.5 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 2.2 MB | ||
| 2025-07-30 00:00 |
AGM Information
임시주주총회결과
|
Korean | 9.2 KB | ||
| 2025-07-24 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 100.9 KB | ||
| 2025-07-24 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.2 KB | ||
| 2025-07-24 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-07-07 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 61.1 KB | ||
| 2025-06-30 00:00 |
Regulatory Filings
[기재정정]단일판매ㆍ공급계약체결(자율공시)
|
Korean | 19.9 KB | ||
| 2025-06-24 00:00 |
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
|
Korean | 41.3 KB | ||
| 2025-06-24 00:00 |
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
|
Korean | 41.2 KB |
Automate Your Workflow. Get a real-time feed of all SAM CHUN DANG PHARM CO. LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for SAM CHUN DANG PHARM CO. LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SAM CHUN DANG PHARM CO. LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
United States of America
LBRX
Develops tissue grafts, medical devices, and cosmetics for tissue regeneration medicine.
South Korea
290650
South Korea
290650
Clinical-stage biopharma developing targeted immuno-oncology antibody therapies for cancer.
United States of America
LPTX
United States of America
LPTX
Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.
United States of America
LEGN
United States of America
LEGN
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
United States of America
LENZ
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
United States of America
LXEO
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
United States of America
LXRX
Develops oncology drugs using a technology for local, controlled, and sustained drug release.
Sweden
LIDDS
Sweden
LIDDS
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
United States of America
LFCR
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
United States of America
LIMN